Answers are grounded in this paper and cite their sources.
Targeted Radionuclide Therapies (TRTs) based on Auger emitting radionuclides have the potential to deliver extremely selective therapeutic payloads on the cellular level. However, to fully exploit this potential, suitable radionuclides need to be applied in combination with appropriate delivery systems. In this review, we summarize the state-of-the-art production, purification, chelation and applications of two promising candidates for Targeted Auger Therapy, namely antimony- 119 (¹¹⁹Sb) and mercury-197 (¹⁹⁷Hg). Both radionuclides have great potential to become efficient tools for TRT. We also highlight our current progress on the production of both radionuclides at TRIUMF and the University of Wisconsin.
No takes yet. Share an insight, caveat, or question.
Randhawa et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: